ETBI Stock Overview
Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Eastgate Biotech Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.008 |
| 52 Week High | US$0.01 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | -11.11% |
| 3 Month Change | n/a |
| 1 Year Change | 247.83% |
| 3 Year Change | 60.00% |
| 5 Year Change | 5.26% |
| Change since IPO | -96.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| ETBI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -3.2% | -3.5% |
| 1Y | 247.8% | 11.7% | 20.2% |
Return vs Industry: ETBI exceeded the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: ETBI exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| ETBI volatility | |
|---|---|
| ETBI Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ETBI's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ETBI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Rose Perri | www.EastGateBiotech.com |
Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions containing natural essential oils for oral administration; Glucora, a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration; URBAN POWER, a soft gelatin capsule with Ursolic acid and Banaba extract in self-emulsifying formulation for oral administration; Vitamin D3 nanoemulsion, a nanoemulsion with cholecalciferol; and Cleanezze, a hand sanitizer containing oil.
Eastgate Biotech Corp. Fundamentals Summary
| ETBI fundamental statistics | |
|---|---|
| Market cap | US$16.46m |
| Earnings (TTM) | -US$3.82m |
| Revenue (TTM) | US$137.64k |
0.0x
P/S Ratio0.0x
P/E RatioIs ETBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETBI income statement (TTM) | |
|---|---|
| Revenue | US$137.64k |
| Cost of Revenue | US$149.28k |
| Gross Profit | -US$11.64k |
| Other Expenses | US$3.81m |
| Earnings | -US$3.82m |
Last Reported Earnings
Sep 30, 2017
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did ETBI perform over the long term?
See historical performance and comparison